Overview
Prognostic indicators of outcome are necessary in order that one can accurately evaluate the impact of current treatment, the relative impact of randomized treatments, and the necessity of treatment intervention and timing thereof in malignant disease of the genitourinary tract. Histopathologic, biochemical, genetic, and physical characteristics of renal adenocarcinomas, transitional cell tumors of the bladder, and adenocarcinomas of the prostate have been evaluated to determine the impact of these variables in predicting outcome of surgical and non-surgical therapies. In certain instances, e.g. prostate, these variables have been evaluated with respect to patient age in order to produce profiles to assist in surgically related patient care decisions. These analyses have proven important in developing outcome analytic strategies appropriate for randomized therapeutic trials and appear to be important in determining cost-related intervention issues that apply in the current managed care environment.
Current Appointments & Affiliations
Education, Training & Certifications
Duke University ·
1964
M.D.